The long -acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment see

DSpace Repositorium (Manakin basiert)

The long -acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment see

Autor(en): Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann
Tübinger Autor(en):
Heyne, Nils
Erschienen in: Kidney International (2020), Bd. 97, H. 6, S. 1287-1296
Verlagsangabe: Elsevier Science Inc
Sprache: Englisch
Referenz zum Volltext: http://dx.doi.org/10.1016/j.kint.2020.01.035
ISSN: 1523-1755
DDC-Klassifikation: 610 - Medizin, Gesundheit
Dokumentart: Wissenschaftlicher Artikel
Zur Langanzeige

Das Dokument erscheint in: